Kidney Cancer Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

In Vivo Models of RCC Genetically engineered mouse models in ccRCC
Payal Kapur, M.D. Associate Professor of Pathology and Urology, UTSW Group Leader Genitourinary Pathology, UTSW Kidney Cancer Program co-leader, Simmons Cancer Center discusses In Vivo Models of RCC G... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

3-dimensional (3D) Organoids for Renal Cell Carcinoma Research
Leigh Ellis Ph.D. Assistant Professor Department of Oncologic Pathology Dana-Farber Cancer Institute Brigham and Womens Hospital Harvard Medical School discusses 3-dimensional (3D) Organoids for Rena... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Cell line and PDX models in renal cell carcinoma
Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery Affiliate Member Department of Computational Biology discusses Cell line and PDX models in renal cell carcinoma at the 2017 Kid... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Neoadjuvant/Presurgical Therapy for RCC: Lessons Learned
Viraj A. Master of Emory University discusses Neoadjuvant Presurgical Therapy for RCC: Lessons Learned at the 2017 Kidney Cancer Association symposium in Miami, FL. Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Perspectives on Adjuvant Trials
Tim Eisen University of Cambridge discusses Perspective(s) on Adjuvant Trials at the 2017 Kidney Cancer Association symposium in Miami, FL. Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Challenges in SURTIME and CARMENA
Axel Bex, MD, PhD The Netherlands Cancer Institute Amsterdam, The Netherlands outlines the Challenges in SURTIME and CARMENA at the 2017 Kidney Cancer Association symposium in Miami, FL. Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Imaging in Renal Cell Carcinoma: Novel Methods and Approaches
Mark W. Ball, MD Staff Clinician | Assistant Research Physician Urologic Oncology Branch National Cancer Institute National Institutes of Health discusses Imaging in Renal Cell Carcinoma: Novel Metho... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Guidelines on Managing SRMs: Compare and Contrast
R. Houston Thompson, MD Professor of Urology Mayo Clinic, Rochester, MN @HThompsonMD presents Guidelines on Managing SRMs: Compare and Contrast at the 2017 Kidney Cancer Association symposium in Miami... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Nephrometry: 21st Century Phrenology
John T. Leppert, MD MS Associate Professor, Stanford University Director of Urologic Oncology, VA Palo Alto @johnleppert presents Nephrometry: 21st Century Phrenology at the 2017 Kidney Cancer Assoc... Author: kidneycancer Added: 11/08/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 9, 2017 Category: Cancer & Oncology Source Type: podcasts

Predictive genomic markers of response to VEGF targeted therapy (TT) in metastatic renal cell carcinoma (mRCC): Role of VHL and TP53 mutation, and FLT1 germline variant
Andrew W. Hahn, MD University of Utah Huntsman Cancer Institute @onchahn discusses Predictive genomic markers of response to VEGF targeted therapy (TT) in metastatic renal cell carcinoma (mRCC): Role... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts

Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis of AXIS and METEOR Trials
IRINA PROSKOROVSKY, MSC discusses Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatm... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts

TiNivo A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma
Laurence Albiges, MD, PhD Institut Gustave Roussy Villejuif, France gives an overview of TiNivo A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma at the 2017 Kidney ... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts

Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective Experience
Michael Roger Harrison, MD of Duke University presents Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective Experience at the 2017 Kidney Cancer Association sy... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts

A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer
ALEXANDRA DRAKAKI, MD, PHD UNIVERSITY OF CALIFORNIA LOS ANGELES gives an overview of A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts

DART Study A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial
Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Re... Author: kidneycancer Added: 11/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - November 8, 2017 Category: Cancer & Oncology Source Type: podcasts